962 related articles for article (PubMed ID: 28429198)
21. Overview of direct oral anticoagulant therapy reversal.
Gulseth MP
Am J Health Syst Pharm; 2016 May; 73(10 Suppl 2):S5-S13. PubMed ID: 27147458
[TBL] [Abstract][Full Text] [Related]
22. Periprocedural Management of Oral Anticoagulation.
Shaw JR; Kaplovitch E; Douketis J
Med Clin North Am; 2020 Jul; 104(4):709-726. PubMed ID: 32505262
[TBL] [Abstract][Full Text] [Related]
23. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
Leung TS; Law EH
Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
[TBL] [Abstract][Full Text] [Related]
24. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
Desai NR; Cornutt D
Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
[TBL] [Abstract][Full Text] [Related]
25. Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.
Samos M; Stanciakova L; Skornova I; Bolek T; Kovar F; Stasko J; Galajda P; Mokan M; Kubisz P
Curr Drug Metab; 2017; 18(7):643-650. PubMed ID: 28412907
[TBL] [Abstract][Full Text] [Related]
26. Reversal of direct oral anticoagulants.
Almegren M
Vasc Health Risk Manag; 2017; 13():287-292. PubMed ID: 28769570
[TBL] [Abstract][Full Text] [Related]
27. Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants.
Chan NC; Bhagirath V; Dale BJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2015 Nov; 13(11):1213-23. PubMed ID: 26471327
[TBL] [Abstract][Full Text] [Related]
28. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
Darius H
Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants.
Andresen K; Atar D; Gjertsen E; Ghanima W; Roseth S; Johansen OE
Scand Cardiovasc J; 2018 Jun; 52(3):156-162. PubMed ID: 29569500
[TBL] [Abstract][Full Text] [Related]
30. Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal.
Karcioglu O; Zengin S; Ozkaya B; Ersan E; Yilmaz S; Afacan G; Abuska D; Hosseinzadeh M; Yeniocak S
Cardiovasc Hematol Agents Med Chem; 2022; 20(2):103-113. PubMed ID: 34521332
[TBL] [Abstract][Full Text] [Related]
31. Italian intersociety consensus on DOAC use in internal medicine.
Prisco D; Ageno W; Becattini C; D'Angelo A; Davì G; De Cristofaro R; Dentali F; Di Minno G; Falanga A; Gussoni G; Masotti L; Palareti G; Pignatelli P; Santi RM; Santilli F; Silingardi M; Tufano A; Violi F; ; ;
Intern Emerg Med; 2017 Apr; 12(3):387-406. PubMed ID: 28191610
[TBL] [Abstract][Full Text] [Related]
32. Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants.
Sarode R; Welsby IJ; Hoffman M
Ann Emerg Med; 2023 Sep; 82(3):341-361. PubMed ID: 37204347
[TBL] [Abstract][Full Text] [Related]
33. Direct oral anticoagulants: a review on the current role and scope of reversal agents.
Chaudhary R; Sharma T; Garg J; Sukhi A; Bliden K; Tantry U; Turagam M; Lakkireddy D; Gurbel P
J Thromb Thrombolysis; 2020 Feb; 49(2):271-286. PubMed ID: 31512202
[TBL] [Abstract][Full Text] [Related]
34. Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper.
Ageno W; Büller HR; Falanga A; Hacke W; Hendriks J; Lobban T; Merino J; Milojevic IS; Moya F; van der Worp HB; Randall G; Tsioufis K; Verhamme P; Camm AJ
Thromb Haemost; 2016 Nov; 116(6):1003-1010. PubMed ID: 27488232
[TBL] [Abstract][Full Text] [Related]
35. Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding.
Grottke O; Afshari A; Ahmed A; Arnaoutoglou E; Bolliger D; Fenger-Eriksen C; von Heymann C
Eur J Anaesthesiol; 2024 May; 41(5):327-350. PubMed ID: 38567679
[TBL] [Abstract][Full Text] [Related]
36. Reversing the anticoagulation effects of dabigatran.
Dager WE; Banares L
Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
[TBL] [Abstract][Full Text] [Related]
37. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
38. Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants.
Dager W; Hellwig T
Am J Health Syst Pharm; 2016 May; 73(10 Suppl 2):S14-26. PubMed ID: 27147455
[TBL] [Abstract][Full Text] [Related]
39. Reversal agents for current and forthcoming direct oral anticoagulants.
van Es N; De Caterina R; Weitz JI
Eur Heart J; 2023 May; 44(20):1795-1806. PubMed ID: 36988142
[TBL] [Abstract][Full Text] [Related]
40. Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience.
Eikelboom J; Merli G
Am J Med; 2016 Nov; 129(11S):S33-S40. PubMed ID: 27586367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
